Pain Therapeutics, Inc. (PTIE) Stock Is At All-Time on Jun, 29

June 29, 2018 - By Tyler Harlow

On Jun, 29, all time low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s share price was $2.14. It’s 6.00 % below our $2.01. announced this technical setup. The company has $14.76M market cap. At $2.01 stock price target, the company valuation changes by $885,360 less.

Ticker’s shares touched $2.14 during the last trading session after 5.10% change.Pain Therapeutics, Inc. has 274,326 shares volume, 132.03% up from normal. PTIE is uptrending and has moved 133.72% since June 29, 2017. PTIE outperformed the S&P 500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news announced recently go to:,,, or The titles are as follows: “Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER” announced on June 26, 2018, “20 Stocks Moving In Thursday’s Pre-Market Session” on June 28, 2018, “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” with a publish date: June 28, 2018, “Pain Therapeutics’ stock plummets 70% after FDA advisory panel vote disappoints” and the last “Key events next week – healthcare” with publication date: June 21, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is valued at $14.76 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: